drugset / Trial / NCT02559180

Treatment of Diabetic Macular Edema With Aflibercept in Subjects Previously Treated With Ranibizumab or Bevacizumab

NCT02559180

Phase 4 Completed 20 enrolled Rishi Singh Regeneron Pharmaceuticals · collab
NaSingle-groupOpen-labelTreatment

Summary

Treatment of diabetic macular edema with intravitreal aflibercept in subjects previously treated with intravitreal anti-Vascular endothelial growth factor (VEGF) agents (ranibizumab or bevacizumab)

Timeline

Start
2015-10
Primary completion
2020-12
Completion
2020-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Aflibercept Protein / enzyme biologic 2 mg Intravitreal